Clinical trials for relapsed/refractory Hodgkin lymphoma
| Trial . | Phase . | Details . | N (est) . | Sponsor/location . | Clinicaltrials.gov . |
|---|---|---|---|---|---|
| Checkpoint inhibitor combinations (include PD-1 refractory) | |||||
| Magrolimab and pembrolizumab | 2 | Magrolimab: anti-CD47 mAb | 24 | Stanford/Merck | NCT04788043 |
| Favezilumab/pembrolizumab vs physician's choice (bendamustine or gemcitabine) | 3 | 360 | Merck | NCT05508867 | |
| Nivolumab and axatilimab | 2 | Axatilimab: mAb inhibits CSF-1R | 9 | University of Utah | NCT05723055 |
| Azacitidine and nivolumab | 1 | 30 | City of Hope | NCT05162976 | |
| Azacitidine and pembrolizumab | 2 | 24 | MDACC | NCT05355051 | |
| Chidamide/decitabine/camrelizumab vs decitabine/camrelizumab | 2 | Chidamide: HDAC inhibitor | 200 | Chinese PLA General Hospital | NCT04514081 |
| PD-1 inhibitor after CD30 CAR-T cell therapy | 1 | Patients who progressed after CD30 CAR-T | 20 | University of North Carolina | NCT04134325 |
| Novel agents | |||||
| AZD4573 | 2 | AZD4573–CDK9 inhibitor | 81 | AstraZeneca | NCT05140382 |
| SHR1701 alone or in combination with SHR2554 | 1/2 | SHR-1701: bifunctional fusion protein targeting PDL1 and TGF-B SHR2554–EZH2 inhibitor | 100 | Chinese PLA General Hospital | NCT05896046 |
| AZD7789 | 1/2 | AZD7789: anti–PD-1/TIM3 bispecific antibody | 180 | AstraZeneca | NCT05216835 |
| Adoptive cell therapies | |||||
| CD30 CAR-T cells (HSP-CAR30) | 1/2A | 30 | Fundacio Institut de Recerca de L'Hospital de la Santa Creu I Sant Pau | NCT04653649 | |
| CD30 CAR-T cells | 1 | 20 | Immune Cell, Inc. | NCT03383965 | |
| CD30 CAR-T cells | 1 | 60 | Baylor | NCT02917083 | |
| CD30 CAR-T cells in R/R CD30+ lymphoma | 1 | 9 | Zhejiang University | NCT05208853 | |
| CD30 CAR-T cells | 1b/2 | Pediatric patient cohort only open | 40 | UNC | NCT02690545 |
| CD30 CAR-T cells coexpressing CCR4 | 1 | 59 | UNC | NCT03602157 | |
| CD30biAb-AATC | 1 | Anti-CD30 bispecific antibody-armed, anti-CD3-activated, autologous T cells | 42 | MCW | NCT05544968 |
| Allogeneic CD30.CAR-EBV specific T lymphocytes | 1 | 18 | Baylor | NCT04952584 | |
| AFM13 in combination with AB-101 | 2 | AB-101–allogeneic NK cell therapy | 154 | Affimed | NCT05883449 |
| Trial . | Phase . | Details . | N (est) . | Sponsor/location . | Clinicaltrials.gov . |
|---|---|---|---|---|---|
| Checkpoint inhibitor combinations (include PD-1 refractory) | |||||
| Magrolimab and pembrolizumab | 2 | Magrolimab: anti-CD47 mAb | 24 | Stanford/Merck | NCT04788043 |
| Favezilumab/pembrolizumab vs physician's choice (bendamustine or gemcitabine) | 3 | 360 | Merck | NCT05508867 | |
| Nivolumab and axatilimab | 2 | Axatilimab: mAb inhibits CSF-1R | 9 | University of Utah | NCT05723055 |
| Azacitidine and nivolumab | 1 | 30 | City of Hope | NCT05162976 | |
| Azacitidine and pembrolizumab | 2 | 24 | MDACC | NCT05355051 | |
| Chidamide/decitabine/camrelizumab vs decitabine/camrelizumab | 2 | Chidamide: HDAC inhibitor | 200 | Chinese PLA General Hospital | NCT04514081 |
| PD-1 inhibitor after CD30 CAR-T cell therapy | 1 | Patients who progressed after CD30 CAR-T | 20 | University of North Carolina | NCT04134325 |
| Novel agents | |||||
| AZD4573 | 2 | AZD4573–CDK9 inhibitor | 81 | AstraZeneca | NCT05140382 |
| SHR1701 alone or in combination with SHR2554 | 1/2 | SHR-1701: bifunctional fusion protein targeting PDL1 and TGF-B SHR2554–EZH2 inhibitor | 100 | Chinese PLA General Hospital | NCT05896046 |
| AZD7789 | 1/2 | AZD7789: anti–PD-1/TIM3 bispecific antibody | 180 | AstraZeneca | NCT05216835 |
| Adoptive cell therapies | |||||
| CD30 CAR-T cells (HSP-CAR30) | 1/2A | 30 | Fundacio Institut de Recerca de L'Hospital de la Santa Creu I Sant Pau | NCT04653649 | |
| CD30 CAR-T cells | 1 | 20 | Immune Cell, Inc. | NCT03383965 | |
| CD30 CAR-T cells | 1 | 60 | Baylor | NCT02917083 | |
| CD30 CAR-T cells in R/R CD30+ lymphoma | 1 | 9 | Zhejiang University | NCT05208853 | |
| CD30 CAR-T cells | 1b/2 | Pediatric patient cohort only open | 40 | UNC | NCT02690545 |
| CD30 CAR-T cells coexpressing CCR4 | 1 | 59 | UNC | NCT03602157 | |
| CD30biAb-AATC | 1 | Anti-CD30 bispecific antibody-armed, anti-CD3-activated, autologous T cells | 42 | MCW | NCT05544968 |
| Allogeneic CD30.CAR-EBV specific T lymphocytes | 1 | 18 | Baylor | NCT04952584 | |
| AFM13 in combination with AB-101 | 2 | AB-101–allogeneic NK cell therapy | 154 | Affimed | NCT05883449 |
HDAC, histone deacetylase; mAb, monoclonal antibody; TGF-B, transforming growth factor β.